Retigabine dihydrochloride
CAS No. 150812-13-8
Retigabine dihydrochloride ( Ezogabine,D-23129 )
Catalog No. M22738 CAS No. 150812-13-8
Retigabine dihydrochloride is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients.?The mechanism of action involves opening of neuronal K(V)7.2-7.5 (formerly KCNQ2-5) voltage-activated K(+) channels.In differentiated PC12 cells, retigabine enhanced a linopirdine-sensitive current.?
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 35 | In Stock |
|
50MG | Get Quote | In Stock |
|
100MG | Get Quote | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRetigabine dihydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionRetigabine dihydrochloride is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients.?The mechanism of action involves opening of neuronal K(V)7.2-7.5 (formerly KCNQ2-5) voltage-activated K(+) channels.In differentiated PC12 cells, retigabine enhanced a linopirdine-sensitive current.?
-
DescriptionRetigabine dihydrochloride is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients.?The mechanism of action involves opening of neuronal K(V)7.2-7.5 (formerly KCNQ2-5) voltage-activated K(+) channels.In differentiated PC12 cells, retigabine enhanced a linopirdine-sensitive current.?The effect of retigabine was associated with a slowing of M-like tail current deactivation in these cells.?Retigabine (0.1 to 10 microM) induced a potassium current and hyperpolarized CHO cells expressing KCNQ2/Q3 cells but not in wild-type cells.?Retigabine-induced currents in CHO-KCNQ2/Q3 cells were inhibited by 60.6 +/- 11% (n = 4) by the KCNQ2/Q3 blocker, linopirdine (10 microM), and 82.7 +/- 5.4% (n = 4) by BaCl(2) (10 mM).?The mechanism by which retigabine enhanced KCNQ2/Q3 currents involved large, drug-induced, leftward shifts in the voltage dependence of channel activation (-33.1 +/- 2.6 mV, n = 4, by 10 microM retigabine).?Retigabine shifted the voltage dependence of channel activation with an EC(50) value of 1.6 +/- 0.3 microM (slope factor was 1.2 +/- 0.1, n = 4 to 5 cells per concentration).?Retigabine (0.1 to 10 microM) also slowed the rate of channel deactivation, predominantly by increasing the contribution of a slowly deactivating tail current component.?
-
SynonymsEzogabine,D-23129
-
PathwayCell Cycle/DNA Damage
-
TargetPotassium Channel
-
RecptorKCNQ3/5;KCNQ2/Q3;KCQN4
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number150812-13-8
-
Formula Weight376.25
-
Molecular FormulaC16H20Cl2FN3O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCl.Cl.CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wickenden A D , Yu W , Zou A , et al. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels.[J]. Molecular Pharmacology, 2000, 58(3):591-600.
molnova catalog
related products
-
Amsacrine
Amsacrine (mAMSA) an antineoplastic agent which can intercalate into the DNA of tumor cells.
-
VU591 hydrochloride
VU591 hydrochloride is a selective renal outer medullary potassium channel (Kir1.1, ROMK) antagonist (IC50:0.24 μM).?Thought to block the intracellular pore of the Kir1.1 channel.?Exhibits no effect on Kir7.1 at concentrations up to 10 μM;?does not inhibit Kir2.1, Kir2.3 or Kir4.1.?
-
AUT1
AUT1 (AUT-1) is a novel specific modulator of Kv3 channels (EC50: 4.7 and 4.9 uM for Kv3.1b and Kv3.2a).